Key result
Reticulated platelets in CAD show enhanced activation linked to heightened PI3K and GPVI signaling.
Why the study?
Do PI3K and GPVI inhibitors reduce the hyperreactivity of reticulated platelets in patients with coronary artery disease?
Population
95 patients with coronary artery disease (CAD)
Comparison
In vitro PI3K inhibition and GPVI inhibition vs Mature platelets from the same donors and…
Design
Preclinical
Authors
Loading...
This study provides the first mechanistic explanation for reticulated platelet hyperreactivity in CAD, identifying GPVI and PI3K as potential therapeutic targets for tailored antiplatelet therapy.
Observational (n=95)
Do PI3K and GPVI inhibitors reduce the hyperreactivity of reticulated platelets in patients with coronary artery disease?
This study provides the first mechanistic explanation for reticulated platelet hyperreactivity in CAD, identifying GPVI and PI3K as potential therapeutic targets for tailored antiplatelet therapy.
Kirmes et al. (2025) conducted an observational in coronary artery disease (n=95). Reticulated platelets vs. Mature platelets was evaluated on activation marker expression and prothrombotic pathways. Reticulated platelets in CAD patients exhibited elevated activation marker expression and heightened PI3K and GPVI signalling compared to mature platelets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: